Literature DB >> 14613821

Effects of perinatal loratadine exposure on male rat reproductive organ development.

Barry S McIntyre1, Paul M Vancutsem, Kimberley A Treinen, Richard E Morrissey.   

Abstract

Normal pre- and postnatal male reproductive development and function is dependent upon testicular androgen production and is sensitive to antiandrogenic perturbations. It was of interest to determine if the H(1) histamine antagonist loratadine had the potential to alter androgen-mediated reproductive development in the rat, a sensitive species for detecting antiandrogenic effects. Loratadine was administered orally by gavage to pregnant Sprague-Dawley rats at doses of 4, 12 or 24 mg/kg from gestation day 7 to postnatal day 4, encompassing the period of androgen-dependent male reproductive development. Vehicle control rats received 0.4% aqueous methylcellulose. Dams were allowed to deliver naturally and rear their offspring until postnatal day 21. On postnatal day 21 male offspring were retained for further evaluation of androgen-dependent endpoints and the female offspring were euthanized and their sex confirmed internally. Males were necropsied from postnatal day 72 to 85. Dams administered 24 mg/kg of loratadine exhibited a transient 45% decrement in maternal body weight gain at the initiation of dosing (gestation days 7-9). Mean pup body weight on postnatal days 1 and 4 were approximately 4% lower than controls. No other effects on offspring growth were observed. Anogenital distance on postnatal day 1 was unaffected by loratadine exposure. Loratadine exposure did not induce the retention of nipples in male rats, affect preputial separation, or induce external malformations, including hypospadias. Seminal vesicle and prostate weights were not decreased by loratadine exposure. These data clearly demonstrate that systemic loratadine exposure, in multiples up to 26 times clinical exposure levels, does not exhibit in vivo antiandrogen activity, as evidenced by the absence of alterations or malformations in androgen-dependent reproductive tissues in male rats exposed to loratadine during the critical period of androgen-dependent development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613821     DOI: 10.1016/s0890-6238(03)00108-4

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  4 in total

1.  Assessment of antihistamine use in early pregnancy and birth defects.

Authors:  Qian Li; Allen A Mitchell; Martha M Werler; Wai-Ping Yau; Sonia Hernández-Díaz
Journal:  J Allergy Clin Immunol Pract       Date:  2013-09-12

Review 2.  Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis.

Authors:  Eleanor B Schwarz; Myla E Moretti; Smita Nayak; Gideon Koren
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy.

Authors:  Bengt Källén; Petra Otterblad Olausson
Journal:  Int J Med Sci       Date:  2006-06-01       Impact factor: 3.738

Review 4.  On the Use and Interpretation of Areola/Nipple Retention as a Biomarker for Anti-androgenic Effects in Rat Toxicity Studies.

Authors:  Camilla Lindgren Schwartz; Sofie Christiansen; Ulla Hass; Louise Ramhøj; Marta Axelstad; Nathalie Michelle Löbl; Terje Svingen
Journal:  Front Toxicol       Date:  2021-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.